A review of minimally invasive cosmetic procedures
S. Ogden,
T.W. Griffiths,
S. Ogden
Dermatological Sciences, University of Manchester, Manchester, U.K.
Search for more papers by this authorT.W. Griffiths
Dermatological Sciences, University of Manchester, Manchester, U.K.
Dermatology Department, Macclesfield District General Hospital, Macclesfield, U.K.
Search for more papers by this authorS. Ogden,
T.W. Griffiths,
S. Ogden
Dermatological Sciences, University of Manchester, Manchester, U.K.
Search for more papers by this authorT.W. Griffiths
Dermatological Sciences, University of Manchester, Manchester, U.K.
Dermatology Department, Macclesfield District General Hospital, Macclesfield, U.K.
Search for more papers by this authorStephanie Ogden.E-mail: [email protected]
Conflicts of interestTWG has received speaking fees and honaria from Stiefel, Allergan, Q-Med and Johnson & Johnson and a research grant from Mentor.
Summary
In today’s society the desire to maintain a youthful appearance has driven the development of minimally invasive dermatological procedures that are designed to rejuvenate the ageing face. The aim of this review is to present evidence for the use of techniques which can easily be incorporated into outpatient dermatology practice with low overhead expenditure. For this reason, laser and light-based treatments have been omitted. This review will instead focus on chemical peels, intradermal fillers and botulinum toxin. These techniques address the main aspects of facial ageing, namely photodamage, volume loss and dynamic lines, which correlate anatomically to skin, subcutaneous fat and muscle. A combination of such techniques will provide the practitioner with a reasonable portfolio of treatments for a balanced, holistic result.
References
- 1 Donofrio L. Fat distribution: a morphologic study of the aging face. Dermatol Surg 2000; 26: 1107–12.
- 2 Buss DM. The Evolution of Desire: Strategies of Human Mating. New York: Basic Books, 1994.
- 3 Finn JC, Cox SE, Earl ML. Social implications of hyperdynamic lines. Dermatol Surg 2003; 29: 450–5.
- 4 Kowalski J, Ravelo A, Saulay M, Fraczek S. Patient self-perceptions and satisfaction with botulinum toxin type-A treatment for moderate to severe crow’s feet: results from a placebo-controlled clinical study. Presented at the American Academy of Dermatology 2005; Mtg Book 87 (ABS-137).
- 5 American Society for Aesthetic Plastic Surgery. 11.5 Million Cosmetic Procedures in 2006. 2007. Available at: http://www.surgery.org/press/news-release.php?iid=465 (last accessed 28 July 2008).
- 6 Carruthers JA, Lowe NJ, Menter MA et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840–9.
- 7 Ascher B, Zakine B, Kestemont P et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223–33.
- 8 Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet. J Am Acad Dermatol 2002; 47: 834–40.
- 9 Lowe NJ, Ascher B, Heckmann M et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet. Dermatol Surg 2005; 31: 257–62.
- 10 Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg 2003; 29: 461–7.
- 11 Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31: 414–22.
- 12 Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin A in men with glabellar rhytids. Dermatol Surg 2005; 31: 1297–303.
- 13 Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33: S51–9.
- 14 Rzany B, Ascher B, Fratila A et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142: 320–6.
- 15 Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006; 55: 975–80.
- 16 Carruthers A, Carruthers J, Flynn TC, Leong M. Dose-finding, safety and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg 2007; 33: S60–8.
- 17 Flynn TC, Carruthers J, Carruthers AJ, Clark RE. Botulinum A toxin (Botox) in the lower eyelid: dose-finding study. Dermatol Surg 2003; 29: 943–51.
- 18 Lowe NJ, Yamauchi PS. Cosmetic uses of botulinum toxins for lower aspects of the face and neck. Clin Dermatol 2004; 22: 18–22.
- 19 Lowe NJ, Yamauchi PS, Lask GP et al. Botulinum toxins type A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002; 4: 15–18.
- 20 Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29: 7–13.
- 21 Baumann L, Slezinger A, Vujevich J et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow’s feet: a double-blinded, placebo-controlled trial. Dermatol Surg 2003; 29: 508–15.
- 22 Yamauchi PS, Lowe NJ. Botulinum toxins type A and B: comparison of efficacy, duration, and dose ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol 2004; 22: 34–9.
- 23 Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29: 802–9.
- 24 Batra RS, Dover JS, Arndt KA. Adverse event reporting for botulinum toxin type A. J Am Acad Dermatol 2005; 53: 1080–2.
- 25 Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 2004; 22: 66–75.
- 26 Wollina U, Konrad H. Managing adverse effects associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol 2005; 6: 141–50.
- 27 Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum A exotoxin: report of 5 cases. J Am Acad Dermatol 2002; 46: 62–5.
- 28 Northington ME, Huang CC. Dry eyes and superficial punctate keratitis: a complication of treatment of glabellar dynamic rhytides with botulinum exotoxin A. Dermatol Surg 2004; 30: 1515–17.
- 29 Cox SE, Finn JC, Stetler L et al. Development of the facial lines treatment satisfaction questionnaire and the initial results for botulinum toxin type A-treated patients. Dermatol Surg 2003; 29: 444–9.
- 30 Sommer B, Zschocke I, Bergfeld D et al. Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol Surg 2003; 29: 456–60.
- 31 Carruthers A, Carruthers J, Dessain A. Preliminary results with the facial lines outcomes questionnaire in the treatment of multiple upper facial rhytids with botulinum toxin type A: results from a single center, dose comparison, pilot study. Presented at the American Academy of Dermatology 2005; Mtg Book 88 (ABS-138).
- 32 Carruthers J, Carruthers A. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Dermatol Surg 2007; 33: S10–17.
- 33 Fagien S, Cox SE, Finn JC et al. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2007; 33: S2–9.
- 34 Carruthers J, Carruthers A. Procedures in Cosmetic Dermatology: Soft Tissue Augmentation. Philadelphia: Saunders, 2005.
- 35 Klein AW. Techniques for soft tissue augmentation: an ‘A to Z’. Am J Clin Dermatol 2006; 7: 107–20.
- 36 Matarasso SL, Carruthers JD, Jewell ML; Resylane Consensus Group. Consensus recommendations for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg 2006; 117 (Suppl. 3): 3–34.
- 37 Bauman L. CosmoDerm/CosmoPlast (human bioengineered collagen) for the aging face. Facial Plast Surg 2004; 20: 125–8.
- 38 Sclafani AP, Romo T III. Collagen, human collagen, and fat: the search for a three-dimensional soft tissue filler. Facial Plast Surg 2001; 17: 79–85.
- 39 Stolman LP. Human collagen reactions. Dermatol Surg 2005; 31: 1634.
- 40 Sclafani AP, Romo T III, Jaconi AA. Rejuvenation of the aging lip with an injectable acellular dermal graft (Cymetra). Arch Facial Plast Surg 2002; 4: 252–7.
- 41 Struck H. Immunological investigations of antigenicity and specificity of soluble collagen fractions. IV. Anaphylaxis and allergy experiments. Eur Surg Res 1976; 8: 243–9.
- 42 Monstrey SJ, Pitaru S, Hamdi M et al. A two-stage phase I trial of Evolence30 collagen for soft-tissue contour correction. Plast Reconstr Surg 2007; 120: 303–11.
- 43 Narins RS, Brandt FS, Lorenc ZP et al. A randomized, multicenter study of the safety and efficacy of Dermicol-P35 and non-animal-stabilized hyaluronic acid gel for the correction of nasolabial folds. Dermatol Surg 2007; 33: S213–21.
- 44 Lowe NL, Maxwell CA, Lowe P et al. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol 2001; 45: 930–3.
- 45 McCracken MS, Khan JA, Wulc AE et al. Hyaluronic acid gel (Restylane) filler for facial rhytids: lessons learned from American Society of Ophthalmic Plastic and Reconstructive Surgery member treatment of 286 patients. Ophthal Plast Reconstr Surg 2006; 22: 188–91.
- 46 Narins RS, Brandt F, Leyden J. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29: 588–95.
- 47 Baumann LS, Shamban AT, Lupo MP et al. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007; 33: S128–35.
- 48 Lindqvist C, Tveten S, Bondevik BE, Fagrell D. A randomized, evaluator-blind, multicenter comparison of the efficacy and tolerability of Perlane versus Zyplast in the correction of nasolabial folds. Plast Reconstr Surg 2005; 115: 282–9.
- 49 Wang F, Garza LA, Kang S et al. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007; 143: 155–63.
- 50 Monheit G, Coleman KM. Hyaluronic acid fillers. Dermatol Ther 2006; 19: 141–50.
- 51 Beer K. A randomized, evaluator blinded comparison of efficacy of hyaluronic acid gel and avian-sourced Hylan B Plus gel for correction of nasolabial folds. Dermatol Surg 2007; 33: 928–36.
- 52 Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002; 28: 491–4.
- 53 Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material: report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 2004; 114: 964–76.
- 54 Cohen SR, Berner CF, Busso M et al. Artefill: a long-lasting injectable wrinkle filler material – summary of the U.S. Food and Drug Administration trials and a progress report on 4- to 5-year outcomes. Plast Reconstr Surg 2006; 118 (Suppl. 3): S64–76.
- 55 Klein AW. Soft tissue augmentation 2006: filler fantasy. Dermatol Ther 2006; 19: 129–33.
- 56 Bergeret-Galley C, Latouche X, Illouz Y-G. The value of a new filler material in corrective and cosmetic surgery: DermaLive and DermaDeep. Aesthetic Plast Surg 2001; 25: 249–55.
- 57 Angus JE, Affleck AG, Leach IH, Millard LG. Two cases of delayed granulomatous reactions to the cosmetic filler Dermalive, a hyaluronic acid and acrylic hydrogel. Br J Dermatol 2006; 155: 1077–8.
- 58 Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006; 118: S22–30.
- 59 Jacovella PF, Peiretti CB, Cunille D et al. Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plast Reconstr Surg 2006; 118: S15–21.
- 60 Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus associated lipoatrophy: one year durability. Plast Reconstr Surg 2006; 118: S34–45.
- 61 Smith S, Busso M, McClaren M, Bass LS. A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds. Dermatol Surg 2007; 33: S112–21.
- 62 Moers-Carpi M, Vogt S, Santos BM et al. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 2007; 33: S144–51.
- 63 Roy D, Sadick N, Mangat D. Clinical trial of a novel filler material for soft tissue augmentation of the face containing synthetic calcium hydroxylapatite microspheres. Dermatol Surg 2006; 32: 1134–9.
- 64 Kanchwala SK, Holloway L, Bucky LP. Reliable soft tissue augmentation. A clinical comparison of injectable soft tissue fillers for facial-volume augmentation. Ann Plast Surg 2005; 55: 30–5.
- 65 Woerle B, Hanke CW, Sattler G. Poly-l-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 2004; 3: 385–9.
- 66 Narins RS, Beer K. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg 2006; 118: S77–84.
- 67 Duffy DM. Liquid silicone for soft tissue augmentation. Dermatol Surg 2005; 31: 1530–41.
- 68 Jones DH, Carruthers A, Orentreich D et al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004; 30: 1279–86.
- 69 Zakapoulu N, Kontochristopoulos MD, Kontochristopoulos G. Superficial chemical peels. J Cosmet Dermatol 2006; 5: 246–53.
- 70 Landau M. Combination of chemical peelings with botulinum toxin injections and dermal fillers. J Cosmet Dermatol 2006; 5: 121–6.
- 71 Butler PE, Gonzalez S, Randolph MA et al. Quantitative and qualitative effects of chemical peeling on photo-aged skin: an experimental study. Plast Reconstr Surg 2001; 107: 222–8.
- 72 Brody HJ. Complications of chemical resurfacing. Dermatol Clin 2001; 19: 427–38.
- 73 Bernstein EF, Lee J, Brown DB et al. Glycolic acid treatment increases type I collagen mRNA and hyaluronic acid content of human skin. Dermatol Surg 2001; 27: 429–33.
- 74 Newman N, Newman A, Moy LS et al. Clinical improvement of photoaged skin with 50% glycolic acid. A double-blind vehicle-controlled study. Dermatol Surg 1996; 22: 455–60.
- 75 Bernstein EF. Chemical peels. Semin Cutan Med Surg 2002; 21: 27–45.
- 76 Kligman D, Kligman AM. Salicylic acid peels for the treatment of photoaging. Dermatol Surg 1998; 24: 325–8.
- 77 Otley CC, Roenigk RK. Medium-depth chemical peeling. Semin Cutan Med Surg 1996; 15: 145–54.
- 78 Humphreys TR, Werth V, Dzubow L, Kligman A. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. J Am Acad Dermatol 1996; 34: 638–44.
- 79 Tse Y, Ostad A, Lee HS et al. A clinical and histologic evaluation of two medium-depth peels. Glycolic acid versus Jessner’s trichloroacetic acid. Dermatol Surg 1996; 22: 781–6.
- 80 Reed JT, Joseph AK, Bridenstine JB. Treatment of periorbital wrinkles. A comparison of the SilkTouch carbon dioxide laser with a medium-depth chemical peel. Dermatol Surg 1997; 23: 643–8.
- 81 Ghersetich I, Brazzini B, Peris K et al. Pyruvic acid peels for the treatment of photoaging. Dermatol Surg 2004; 30: 32–6.
- 82 Berardesca E, Cameli N, Primavera G, Carrera M. Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel. Dermatol Surg 2006; 32: 526–31.
- 83 Matarasso SL, Brody HJ. Deep chemical peeling. Semin Cutan Med Surg 1996; 15: 155–61.
- 84 Stone PA. The use of modified phenol for chemical face peeling. Clin Plast Surg 1998; 25: 21–44.
- 85 Moy LS, Kotler R, Lesser T. The histologic evaluation of pulsed carbon dioxide laser resurfacing versus phenol chemical peels in vivo. Dermatol Surg 1999; 25: 597–600.
- 86 Hetter GP. An examination of the phenol–croton oil peel: part IV. Face peel results with different concentrations of phenol and croton oil. Plast Reconstr Surg 2000; 105: 1061–83.
- 87 Chew J, Gin I, Rau KA et al. Treatment of upper lip wrinkles: a comparison of 950 microsec dwell time carbon dioxide laser with unoccluded Baker’s phenol chemical peel. Dermatol Surg 1999; 25: 262–6.
